E5501: phase II study of topotecan sequenced with etoposide/ cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Taofeek K OWONIKOKO; Joseph AISNER; XIN VICTORIA WANG; Suzanne E DAHLBERG; Eric H RUBIN; Suresh S RAMALINGAM; Murugesan GOUNDER; Paul Gregory RAUSCH; Rita S AXELROD; Joan H SCHILLER

doi:10.1007/s00280-013-2338-z

Back

E5501: phase II study of topotecan sequenced with etoposide/ cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Journal article

Open access

Peer reviewed

E5501: phase II study of topotecan sequenced with etoposide/ cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Taofeek K OWONIKOKO, Joseph AISNER, XIN VICTORIA WANG, Suzanne E DAHLBERG, Eric H RUBIN, Suresh S RAMALINGAM, Murugesan GOUNDER, Paul Gregory RAUSCH, Rita S AXELROD and Joan H SCHILLER

Cancer chemotherapy and pharmacology, Vol.73(1), pp.171-180

2014

DOI: https://doi.org/10.1007/s00280-013-2338-z

PMCID: PMC4705842

PMID: 24288121

Abstract

Pharmacology. Drug treatments

Tumors of the respiratory system and mediastinum

Biological and medical sciences

Multiple tumors. Solid tumors. Tumors in childhood (general aspects)

Medical sciences

Antineoplastic agents

Tumors

Pneumology

Files and links (1)

url

https://doi.org/10.1007/s00280-013-2338-zView

Version of Record (VoR) Open

Metrics

7 Record Views

4 Times Cited - Web of Science

See more details

Details

Title: E5501: phase II study of topotecan sequenced with etoposide/ cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
Creators: Taofeek K OWONIKOKO - Emory University, Atlanta, GA, United States
Joseph AISNER - Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901-1914, United States
XIN VICTORIA WANG - Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States
Suzanne E DAHLBERG - Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States
Eric H RUBIN - Merck Research Laboratories, North Wales, PA, United States
Suresh S RAMALINGAM - Emory University, Atlanta, GA, United States
Murugesan GOUNDER - Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901-1914, United States
Paul Gregory RAUSCH - Frederick Memorial Hospital, Frederick, MA, United States
Rita S AXELROD - Thomas Jefferson University, Philadelphia, PA, United States
Joan H SCHILLER - University of Texas Southwestern Medical Center, Dallas, TX, United States
Publication Details: Cancer chemotherapy and pharmacology, Vol.73(1), pp.171-180
Date published: 2014
Publisher: Springer
Academic Unit: Lung Cancer/Thoracic Oncology Program
Language: English
Resource Type: Journal article
Identifiers: 991031654552904646